Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21576127 | 0.84 | KMT2A (0.44) | KMT2AL3MBTL1P2RX7KDM4CMAPK1 | |
| SCHEMBL21576217 | 0.83 | P2RX7 (0.50) | KMT2AL3MBTL1P2RX7KDM4CMAPK1 | |
| SCHEMBL21576234 | 0.81 | KMT2A (0.49) | KMT2AL3MBTL1P2RX7KDM4CMAPK1 | |
| SCHEMBL6133307 | 0.81 | MAPK1 (0.50) | KMT2AL3MBTL1P2RX7KDM4CMAPK1 | |
| SCHEMBL22572293 | 0.81 | RAB9A (0.38) | KMT2AL3MBTL1MAPK1POLBHTT | |
| SCHEMBL26085395 | 0.80 | KMT2A (0.39) | KMT2AL3MBTL1P2RX7KDM4CFNTA | |
| SCHEMBL24159039 | 0.79 | KMT2A (0.47) | KMT2AL3MBTL1P2RX7KDM4CMAPK1 | |
| SCHEMBL21576740 | 0.78 | KMT2A (0.46) | KMT2AL3MBTL1P2RX7KDM4CMAPK1 | |
| SCHEMBL21576961 | 0.76 | MAPK1 (0.34) | P2RX7MAPK1PIK3CD | |
| SCHEMBL21576138 | 0.73 | KMT2A (0.45) | KMT2AL3MBTL1P2RX7KDM4CFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KMT2A 2456/4885L3MBTL1 616/4885P2RX7 4351/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | KMT2A 2456/4885L3MBTL1 616/4885P2RX7 4351/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KMT2A 2456/4885L3MBTL1 616/4885P2RX7 4351/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KMT2A 2456/4885L3MBTL1 616/4885P2RX7 4351/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | KMT2A 2456/4885L3MBTL1 616/4885P2RX7 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.